|
| Media |
|
| | |
|
| Press Releases |
| 17 November 2008 |
Abingdon Life Sciences, Inc. Extends Strategic Alliances with Stason Pharmaceuticals, Inc. to Provide Regulatory and Clinical Support to Asian Pharmaceutical and Biotech Companies |
|
| 4 August 2008 |
Abingdon Life Sciences, Inc. Enters into Strategic Alliance with Stason Pharmaceuticals, Inc. to Provide Regulatory and Clinical Support |
|
| 21 July 2008 |
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca. |
|
|
ABINGDON LIFE SCIENCES, INC. EXTENDS STRATEGIC ALLIANCE WITH STASON PHARMACEUTICALS, INC. TO PROVIDE REGULATORY AND CLINICAL SUPPORT TO ASIAN PHARMACEUTICAL AND BIOTECH COMPANIES
Carlsbad, CA, November 17th, 2008
Abingdon Life Sciences, Inc. and Stason Pharmaceuticals, Inc. have extended their strategic alliance announced on August 4th, 2008. Abingdon will utilize the resources of Stason Pharma Japan Co. Ltd. to enhance their business development and IP licensing opportunities in Asia. Abingdon will also offer strategic planning, clinical development and regulatory science support for companies in Japan and throughout Asia wishing to register pharmaceuticals, biotech products and medical devices in the United States via Stason Pharma Japan.
"This expansion will compliment Abingdon’s continued growth within the US and is a major step forward in the current economical climate. Our relationship with Stason has been beneficial for both companies and we believe this expansion will further strengthen the alliance," said Richard Lebovitz, Abingdon CEO. Hiro Hirota, President, Stason Pharma Japan added "Abingdon’s strategic expansion is good news for many Japanese pharmaceutical and biotech companies who need clinical and regulatory support for their business expansion into the US market. Stason Pharma Japan will be playing an important role to develop new business opportunities between Abingdon and Asian companies, particularly in Japan. "
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.
About Stason Pharmaceuticals, Inc.:
Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.
For More Information Contact:
Abingdon Contact:
Aidan Nuttall, Ph.D.
(1) 760-268-1078
anuttall@abingdoncorp.com
Stason Contact:
Diana Wood
(1) 760-929-0346
diana.wood@stasonpharma.com
|
|
|
ABINGDON LIFE SCIENCES, INC. ENTERS INTO STRATEGIC ALLIANCE WITH STASON PHARMACEUTICALS, INC. TO PROVIDE REGULATORY AND CLINICAL SUPPORT
Carlsbad, CA, August 4th, 2008
Abingdon Life Sciences, Inc. has entered into an agreement with Stason Pharmaceuticals, Inc. to provide clinical and regulatory support for Stason's drug development programs. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason's pipeline of potential drug candidates and devices in the areas of cancer and inflammation.
"We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing," said Richard Lebovitz, Abingdon CEO. Harry Fan, CEO of Stason added "Stason is pleased to have agreed to this strategic partnership with Abingdon. It is a mutually beneficial relationship bringing expertise in many areas to our clients, both here in the US and in our overseas markets."
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.
About Stason Pharmaceuticals, Inc.:
Founded in 1994, Stason Pharmaceuticals, Inc. has evolved into a vertically integrated cGMP contract development organization with affiliates and locations in Texas, Massachusetts, Japan, China and Taiwan that provide complete turn-key drug development solutions for API, prototype and final product, clinical supplies for all phases, and commercial production and distribution. Stason also out-licenses internally developed technologies to companies worldwide. Stason is specialized in developing and processing high-potency products, including oncology drugs.
For More Information Contact:
Abingdon Contact:
Aidan Nuttall, Ph.D.
(1) 760-268-1078
anuttall@abingdoncorp.com
Stason Contact:
Diana Wood
(1) 760-929-0346
diana.wood@stasonpharma.com
|
|
|
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
CARLSBAD, Calif., July 21 /PRNewswire/
Abingdon Life Sciences
announces the formal opening of its offices in Carlsbad, California. The offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences, Inc. is a first-in-class Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model. An integrated development model focuses on the Target Product Profile (TPP) concept, and allows a platform to be assessed by key areas of opportunity and risk from both scientific and business aspects.
Abingdon was founded on the principle that a proactive strategic approach to development will yield better outcomes. Abingdon's philosophy is to provide clients with a focused approach to product development by building synergistic partnerships that use significant expertise to achieve the best outcome. Global core-competencies include pre-clinical, regulatory strategy and submissions, clinical development, biostatistics, report writing and post-marketing obligations. Abingdon provides services to clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA, PMA and 510k applications. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience. Key alliances enable Abingdon to assist with cGMP services from formulation development for clinical trial supply through commercialization.
"Abingdon's approach is to reduce the noise in the development process and provide objective direction that outlines the risks and benefits of the potential development pathways. In the end, our goal is to assist our clients to streamline their development process and help make decisions that will achieve their goals. We believe this will ultimately reduce costs to our clients and speed the time to market," stated Aidan Nuttall, Ph.D., President and C.O.O., Abingdon Life Sciences, Inc.
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.
|
|
|
|
|
|
